GLUE — Monte Rosa Therapeutics, Inc. stock price, charts and financials
QT48Monte Rosa Therapeutics, Inc.Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.86 | Insider Own | - | Shs Outstand | 84.48M | Perf Week | -13.79% |
| Market Cap | 1.02B | Forward P/E | - | EPS next Y | -1.90 | Insider Trans | -0.12% | Shs Float | 59.76M | Perf Month | -23.08% |
| Enterprise Value | 441.74M | PEG | - | EPS next Q | -0.23 | Inst Own | - | Short Float | 30.25% | Perf Quarter | -33.75% |
| Income | -39.00M | P/S | 8.26 | EPS this Y | 19.16% | Inst Trans | - | Short Ratio | 12.64 | Perf Half Y | -24.47% |
| Sales | 124.00M | P/B | 2.10 | EPS next Y | -26.18% | ROA | -23.15% | Short Interest | 18.08M | Perf YTD | -22.64% |
| Book/sh | 5.76 | P/C | 1.65 | EPS next 5Y | - | ROE | -43.31% | 52W High | 25.77 -52.93% | Perf Year | 90.72% |
| Cash/sh | 7.35 | P/FCF | - | EPS past 3/5Y | - | ROIC | -28.19% | 52W Low | 6.23 94.70% | Perf 3Y | 102.84% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 92.94% | Volatility | 5.44% 5.45% | Perf 5Y | -65.25% |
| Dividend TTM | - | EV/Sales | 3.56 | EPS Y/Y TTM | -78.57% | Oper. Margin | -633.04% | ATR (14) | 0.85 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.52 | Sales Y/Y TTM | - | Profit Margin | -560.85% | RSI (14) | 27.17 | Recom | 2.22 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.52 | EPS Q/Q | -186.67% | SMA20 | -12.29% | Beta | 1.32 | Target Price | 26.67 |
| Payout | 0.00% | Debt/Eq | 0.15 | Sales Q/Q | -60.87% | SMA50 | -29.21% | Rel Volume | 1.11 | Prev Close | 12.60 |
| Employees | 173 | LT Debt/Eq | 0.15 | Earnings | Nov 05 | SMA200 | -34.25% | Avg Volume | 1.44M | Price | 12.13 |
| IPO Date | Jun 24, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -13.02% -30.31% | Net Debt/EBITDA | 0.33 | Volume | 1,597,816 | Change | -3.73% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Guggenheim | Buy | $35 → $28 |
| Aug-03-26 | Reiterated | Wedbush | Outperform | $37 → $27 |
| Jul-31-26 | Reiterated | Jefferies | Buy | $40 → $25 |
| Jul-27-26 | Reiterated | Jefferies | Buy | $31 → $40 |
| Jun-30-26 | Reiterated | Guggenheim | Buy | $35 |
| Jan-14-26 | Reiterated | Piper Sandler | Overweight | $37 |
| Jan-07-26 | Reiterated | Jefferies | Buy | $22 → $31 |
| Jan-07-26 | Reiterated | Wedbush | Outperform | $26 → $37 |
| Dec-17-25 | Reiterated | Jefferies | Buy | $22 |
| Dec-16-25 | Upgrade | Wells Fargo | Equal Weight → Overweight | $22 |
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 124 | 76 | 0 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 8 | 8 | 6 | — | — | — | — | |
| Gross Profit | 115 | 68 | -6 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 36 | 35 | 32 | — | — | — | — | |
| Research and Development | 142 | 122 | 105 | — | — | — | — | |
| Other Operating Expense | -8 | -8 | 0 | — | — | — | — | |
| Operating Income | -54 | -81 | -143 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 14 | 11 | 8 | — | — | — | — | |
| Net Income Before Taxes | -40 | -70 | -135 | — | — | — | — | |
| Income Taxes | -1 | 3 | 0 | — | — | — | — | |
| Consolidated Net Income | -39 | -73 | -135 | — | — | — | — | |
| Net Income From Continuing Operations | -39 | -73 | -135 | — | — | — | — | |
| Net Income | -39 | -73 | -135 | — | — | — | — | |
| EPS (Recurring) | -0.59 | -0.98 | -2.63 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.59 | -0.98 | -2.63 | — | — | — | — | |
| EPS (Diluted) | -0.59 | -0.98 | -2.63 | — | — | — | — | |
| EBITDA | -31 | -62 | -129 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 8.35 | 6.76 | — | — | — | — | — | |
| Gross Margin | 92.74 | 89.47 | — | — | — | — | — | |
| Operating Margin | -43.55 | -106.58 | — | — | — | — | — | |
| Net Margin | -31.45 | -96.05 | — | — | — | — | — | |
| Shares Outstanding | 66 | 74 | 51 | — | — | — | — | |
| Market Capitalization | 1,035 | 514 | 288 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Warmuth Markus | President & CEO | Jul 16 '26 | Sale | 23.18 | 9,500 | 220,219 | 585,038 | Jul 17 |
| Champoux Jennifer | Chief Operating Officer | Jul 15 '26 | Option Exercise | 3.98 | 4,351 | 17,317 | 66,722 | Jul 16 |
| Champoux Jennifer | Chief Operating Officer | Jul 15 '26 | Sale | 23.38 | 4,351 | 101,730 | 62,371 | Jul 16 |
| Townson Sharon | Chief Scientific Officer | Jul 06 '26 | Sale | 23.31 | 6,000 | 139,849 | 67,845 | Jul 07 |
| Townson Sharon | Chief Scientific Officer | Jul 06 '26 | Option Exercise | 6.14 | 6,000 | 36,840 | 73,845 | Jul 07 |
| Janku Filip | Chief Medical Officer | Jun 30 '26 | Sale | 24.50 | 5,407 | 132,472 | 60,612 | Jul 01 |
| Janku Filip | Chief Medical Officer | Jun 30 '26 | Option Exercise | 13.41 | 5,407 | 72,508 | 66,019 | Jul 01 |
| Manning Anthony M. | Director | Jun 29 '26 | Option Exercise | 4.16 | 10,000 | 41,600 | 10,000 | Jun 30 |
| Janku Filip | Chief Medical Officer | Jun 29 '26 | Option Exercise | 7.56 | 6,000 | 45,360 | 65,992 | Jun 30 |
| Janku Filip | Chief Medical Officer | Jun 29 '26 | Sale | 22.95 | 6,000 | 137,700 | 59,992 | Jun 30 |
| Manning Anthony M. | Director | Jun 29 '26 | Sale | 23.11 | 10,000 | 231,100 | 0 | Jun 30 |
| Janku Filip | Chief Medical Officer | Jun 24 '26 | Option Exercise | 7.56 | 30,000 | 226,800 | 89,992 | Jun 25 |
| Janku Filip | Chief Medical Officer | Jun 24 '26 | Sale | 21.42 | 30,000 | 642,681 | 59,992 | Jun 25 |
| Janku Filip | Chief Medical Officer | Jun 23 '26 | Sale | 20.22 | 11,845 | 239,522 | 59,992 | Jun 25 |
| Champoux Jennifer | Chief Operating Officer | Jun 23 '26 | Option Exercise | 3.98 | 2,175 | 8,657 | 64,546 | Jun 25 |